common.study.topics.clinical

OLANI PK/Safety Study in Healthy Volunteers

common.study.values.description

OLANI PK/Safety Study in Healthy Volunteers

This study will examine the pharmacokinetic profile and safety of the O'Neil Long Acting Naltrexone Implant (OLANI) overtime in healthy volunteers. All participants will be treated in an open label manner. No randomization will occur. It is hypothesized that the OLANI will provide sustained therapeutic doses of naltrexone (NTX) for periods up to 6 months via a single subcutaneous application of 2 OLANIs.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - naltrexone implant

1.8 g implant containing 60% naltrexone

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Pilot Pharmacokinetic (PK) Trial of the O'Neil Long Acting Naltrexone Implant

common.study.values.clinical-trial-id

NCT03810495

participant.views.study.view.id

e73YGe